REGAL Reports an Overall Survival Gain in AML

Company SELLAS Life Sciences Event Type Randomized Phase 3 topline (REGAL) Modality WT1 peptide vaccine Asset Galinpepimut-S (GPS) Target WT1 Disease Area Acute myeloid leukemia in second or later remission Summary SELLAS reported that the randomized Phase 3 REGAL trial met its prespecified overall-survival endpoint…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *